Trials / Terminated
TerminatedNCT01895127
Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation
Efficacy and Safety of Eculizumab for Treatment of Antibody-mediated Rejection Following Renal Transplantation.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 11 (actual)
- Sponsor
- Brigham and Women's Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label analysis that will compare eculizumab versus Plasmapheresis (PP) and Immunoglobulin (IVIg) for the treatment of antibody-mediated rejection (AMR) in renal transplant recipients. All patients will be evaluated from the time of AMR diagnosis for 12 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Eculizumab | |
| BIOLOGICAL | Immunoglobulin | |
| PROCEDURE | Plasmapheresis |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2016-04-01
- Completion
- 2016-04-01
- First posted
- 2013-07-10
- Last updated
- 2017-09-21
- Results posted
- 2017-09-21
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01895127. Inclusion in this directory is not an endorsement.